The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy
Open accessAbstract
OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS). Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis. Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy. RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2−/− mice, and cultured human mesangial cells. RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels. In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage. This is evident by Nrf2−/− mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2+/+ mice. Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-β1 (TGF-β1) and reduction of extracellular matrix production. In human renal mesangial cells, high glucose induced ROS production and activated expression of Nrf2 and its downstream genes. Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-β1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-β1 transcription and fibronectin production. CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,086
Self-citationR�sen, P., Nawroth, P. P., King, G., M�ller, W., Tritschler, H.-J., & Packer, L. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.196 · Cited by 887
Yamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E., & Border, W. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1814 · Cited by 830
An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen
Chan, K., Han, X.-D., & Kan, Y. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081082098 · Cited by 770
Chan, K., Lu, R., Chang, J. C., & Kan, Y. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13943 · Cited by 645
Pathogenesis, prevention, and treatment of diabetic nephropathy
Cooper, M. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01346-4 · Cited by 560
Nrf2 Defends the Lung from Oxidative Stress
Cho, H.-Y., Reddy, S. P., & Kleeberger, S. R. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.76 · Cited by 463
Expression of transforming growth factor-β isoforms in human glomerular diseases
Yamamoto, T., Noble, N. A., Cohen, A. H., Nast, C. C., Hishida, A., Gold, L. I., & Border, W. A. (1996) · Kidney International · doi:10.1038/ki.1996.65 · Cited by 418
Regulatory mechanisms of cellular response to oxidative stress
Itoh, K., Ishii, T., Wakabayashi, N., & Yamamoto, M. (1999) · Free Radical Research · doi:10.1080/10715769900300881 · Cited by 347
Kiritoshi, S., Nishikawa, T., Sonoda, K., Kukidome, D., Senokuchi, T., Matsuo, T., Matsumura, T., Tokunaga, H., Brownlee, M., & Araki, E. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2570 · Cited by 345
Thallas-Bonke, V., Thorpe, S. R., Coughlan, M. T., Fukami, K., Yap, F. Y. T., Sourris, K. C., Penfold, S. A., Bach, L. A., Cooper, M. E., & Forbes, J. M. (2008) · Diabetes · doi:10.2337/db07-1119 · Cited by 345
Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice
Liu, M., Grigoryev, D. N., Crow, M. T., Haas, M., Yamamoto, M., Reddy, S. P., & Rabb, H. (2009) · Kidney International · doi:10.1038/ki.2009.157 · Cited by 304
Gupta, S., Clarkson, M. R., Duggan, J., & Brady, H. R. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00301.x · Cited by 283
Effects of Antioxidants in Diabetes-Induced Oxidative Stress in the Glomeruli of Diabetic Rats
Koya, D., Hayashi, K., Kitada, M., Kashiwagi, A., Kikkawa, R., & Haneda, M. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077412.07578.44 · Cited by 279
Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes
He, X., Kan, H., Cai, L., & Ma, Q. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.10.007 · Cited by 249
Renal disease and hypertension in non–insulin-dependent diabetes mellitus
Ismail, N., Becker, B., Strzelczyk, P., & Ritz, E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00232.x · Cited by 242
Xue, M., Qian, Q., Adaikalakoteswari, A., Rabbani, N., Babaei-Jadidi, R., & Thornalley, P. J. (2008) · Diabetes · doi:10.2337/db06-1003 · Cited by 235
Yoh, K., Hirayama, A., Ishizaki, K., Yamada, A., Takeuchi, M., Yamagishi, S., Morito, N., Nakano, T., Ojima, M., Shimohata, H., et al. (2008) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01234.x · Cited by 207
Fridlyand, L. E., & Philipson, L. H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1363.019 · Cited by 131
Lee, E. A., Seo, J. Y., Jiang, Z., Yu, M. R., Kwon, M. K., Ha, H., & Lee, H. B. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00274.x · Cited by 129
Prevention and treatment of diabetic nephropathy
Wittmann, I., Molnár, G. A., Degrell, P., Wagner, Z., Tamaskó, M., Laczy, B., Brasnyó, P., Wagner, L. J., & Nagy, J. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.011 · Cited by 119
Amelioration of Diabetic Nephropathy in SPARC-Null Mice
Taneda, S., Pippin, J. W., Sage, E. H., Hudkins, K. L., Takeuchi, Y., Couser, W. G., & Alpers, C. E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000054498.83125.90 · Cited by 103
Choi, H., Pokharel, Y. R., Lim, S., Han, H.-K., Ryu, C. S., Kim, S. K., Kwak, M. K., & Kang, K. W. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.030 · Cited by 98
Wei, X. F., Zhou, Q. G., Hou, F. F., Liu, B. Y., & Liang, M. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90536.2008 · Cited by 98
Smad3–ATF3 signaling mediates TGF-β suppression of genes encoding Phase II detoxifying proteins
Bakin, A. V., Stourman, N. V., Sekhar, K. R., Rinehart, C., Yan, X. S., Meredith, M. J., Arteaga, C. L., & Freeman, M. L. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.10.033 · Cited by 97
Roestenberg, P., van Nieuwenhoven, F. A., Joles, J. A., Trischberger, C., Martens, P. P., Oliver, N., Aten, J., Höppener, J. W. M., & Goldschmeding, R. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00174.2005 · Cited by 83
Increased levels of transforming growth factor-β in HIV-associated nephropathy
Yamamoto, T., Noble, N. A., Miller, D. E., Gold, L. I., Hishida, A., Nagase, M., Cohen, A. H., & Border, W. A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00296.x · Cited by 73
Jeong, S., Oh, G., Ha, H.-Y., Koo, B. S., Kim, H. S., Kim, Y., Kim, E.-C., Lee, K.-M., Chung, H., & Pae, H. (2009) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.08-194 · Cited by 65
Transforming growth factor-β1 induces extracellular matrix formation in glomerulonephritis
Border, W. A., & Ruoslahti, E. (1990) · Cell Differentiation and Development · doi:10.1016/0922-3371(90)90059-6 · Cited by 63
Hyperglycemia and intestinal and renal glucose transport: Implications for diabetic renal injury
Debnam, E. S., & Unwin, R. J. (1996) · Kidney International · doi:10.1038/ki.1996.416 · Cited by 33
Cited by
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,542
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
Metadata
- Authors
- Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., & Zhang, D. D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-26
- Volume
- 59
- Issue
- 4
- Pages
- 850-860
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2171439919
- Cited by
- 440
- References
- 31
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.